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Objectives. We compared �ve parathyroid scintigraphy protocols in patients with primary (pHPT) and secondary hyperparathy-
roidism (sHPT) and studied the interobserver agreement. e dual-tracer method (99mTc-sestamibi/123I) was used with three
acquisition techniques (parallel-hole planar, pinhole planar, and SPECT/CT). e single-tracer method (99mTc-sestamibi) was
used with two acquisition techniques (double-phase parallel-hole planar, and SPECT/CT).us �ve protocols were used, resulting
in �ve sets of images. Materials and Methods. Image sets of 51 patients were retrospectively graded by four experienced nuclear
medicine physicians. e �nal study group consisted of 24 patients (21 pHPT, 3 sHPT) who had been operated upon. Surgical
and histopathologic �ndings were used as the standard of comparison. Results. irty abnormal parathyroid glands were found
in 24 patients. e sensitivities of the dual-tracer method (76.7–80.0%) were similar (𝑃𝑃 𝑃 1𝑃𝑃). e sensitivities of the single-
tracer method (13.3–31.6%) were similar (𝑃𝑃 𝑃 𝑃𝑃𝑃2𝑃). All diﬀerences in sensitivity between these two methods were statistically
signi�cant (𝑃𝑃 𝑃 𝑃𝑃𝑃12). e interobserver agreement was good. Conclusion. is study indicates that any dual-tracer protocol with
99mTc-sestamibi and 123I is superior for enlarged parathyroid gland localization when compared with single-tracer protocols using
99mTc-sestamibi alone. e parathyroid scintigraphy was found to be independent of the reporter.
1. Introduction
99mTc-methoxyisobutylisonitrile (99mTc-sestamibi), �rst
introduced by Coakley and coworkers as a parathyroid
imaging agent in 1989 [1], is the imaging agent of choice
for parathyroid scintigraphy (PS) [2]. Unfortunately, 99mTc-
sestamibi is not a speci�c tracer for parathyroid tissue but
is taken up by adjacent thyroid tissue. is problem can be
overcome by using either a single-tracer (double phase) or a
dual-tracer method.
In the single tracer method, it is assumed that thyroid
and parathyroid tissues have diﬀerent washout kinetics for
99mTc-sestamibi [3]. By acquiring images in the early and late
phases, the focally increasing uptake will reveal hyperfunc-
tioning parathyroid tissue. In the dual-tracer method, 99mTc-
sestamibi is used combined with 123I or 99mTc-pertechnetate,
which are taken up by the thyroid gland only. Subtracting
the thyroid image from the 99mTc-sestamibi image provides
visualization of the parathyroid tissue alone [4].
With both single-tracer and dual-tracer methods, several
acquisition techniques can be used (i.e., planar acquisitions
with parallel-hole or pinhole collimators and SPECT or
SPECT/CT), and several choices can be made about the
settings used for each technique (e.g., matrix size, energy
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settings, and acquisition time). ere are several studies that
provide comparisons between the diﬀerent imaging methods
or techniques, although there is little evidence supporting the
superiority of one over another, resulting in the use of various
study protocols today [5, 6].
�e have previously shown that there is signi�cant vari-
ability in the current practice of PS in Finland [7]. is is
also true in other countries, with reported sensitivities for
localizing abnormal parathyroid tissue ranging from 34% to
100% [8].
As a result of our previous study, the clinical protocol of
parathyroid scintigraphy in Satakunta central hospital was
changed in June 2010. Pinhole and SPECT/CT acquisition
techniques were included to increase the sensitivity of the
study. Additional late phase imaging was also included to
bene�t from the double phase method as well.
e goal of this study was to compare the sensitiv-
ity and speci�city of a single-tracer method and a dual-
tracer method with various acquisition techniques. e
dual-tracer method (99mTc-sestamibi/123I) was used with
three acquisition techniques (parallel-hole planar, pinhole
planar, and SPECT/CT). e single-tracer method (99mTc-
sestamibi) was used with two acquisition techniques (double
phase parallel-hole planar, and SPECT/CT). In addition, the
agreement between the �ndings of four experienced nuclear
medicine physicians was studied.
2. Methods
2.1. Patients. is was a retrospective single-center study
of �y-one patients referred for PS between June 2010
and February 2011 in Satakunta Central Hospital, Finland.
Patient data were included if there was biochemical evidence
of hyperparathyroidism, if scintigraphy was requested for
preoperative tumor localization, and if the patient proceeded
to surgery. Histopathological �nding was used as the gold
standard. e �nal study group consisted of 6 men and 18
womenwith amean age of 62.3 years (range, 32.1–86.8 years).
Twenty-one patients had pHPT. Preoperative plasma intact
parathyroid hormone (iPTH) values ranged from 69 ng/L to
277 ng/L (mean 190 ng/L, normal values 10–65 ng/L), and
values for preoperative serum calcium (Ca) ranged from
1.37mmol/L to 1.73mmol/L (mean 1.48mmol/L, normal
values 1.16–1.3mmol/L). ree patients had sHPT due
to renal failure. Preoperative iPTH values ranged from
210 ng/L to 400 ng/L (mean 380 ng/L), values for preoper-
ative Ca ranged from 1.21mmol/L to 1.8mmol/L (mean
1.45mmol/L). Twenty-seven patients did not proceed to
surgery for a variety of reasons (patient condition, death,
and other illnesses). is study was exempt from institu-
tional review board approval according to Finnish legislation.
Informed consent was waived.
2.2. Imaging: Doses and Acquisition. Patients received
20MBq of 123I (MAP Medical Technologies) intravenously.
Two hours later, 550MBq of 99mTc-sestamibi (Mallinckrodt
Medical B.V.) was injected intravenously. Ten minutes aer
the 99mTc-sestamibi administration, imaging was started.
Five diﬀerent image sets were acquired. e order and
the timing (aer the injection or 99mTc-sestamibi) of the
acquisitions and the resulting image sets are presented in
Figure 1.
First, a static 10-minute anterior image of the neck
and chest was acquired using a low-energy, high-resolution,
parallel-hole collimator (LEHR) (256 × 256 matrix; 1.85x
zoom). Next, a static 10-minute anterior image of the neck
was acquired from a distance of 10 cm from the patient’s
skin using a 5mm diameter pinhole collimator (256 × 256
matrix; 2.19x zoom). Acquisitions were performed with the
same dual-head gamma camera (Skylight; Philips). All data
were collected in dual-energy windows. e 99mTc window
was centered at 140 keV and had a 10% width (range,
133–147 keV). e 123I window was centered at 159 keV and
had a 10% width (range, 151–167 keV). Narrow windows
were used to minimize crosstalk between isotopes.
One hour aer the 99mTc-sestamibi injection, the
SPECT/CT acquisition was started (Symbia T; Siemens).
SPECT data were acquired in a step-and-shoot sequence
with a noncircular orbit (180∘ detector con�guration; low-
energy, parallel-hole, high-resolution collimators; 128 ×
128 matrix; 4.8mm pixel size; 48 views for each detector
(3,75∘ per projection); 33 s/projection; total scan time,
32min). All data were collected in dual-energy windows.
e 99mTc window was centered at 140 keV and had a
15% width (range, 129.5–150.5 keV). e 123I window was
placed with a 4% oﬀset above 159 keV and had a 15%
width (range, 153.4–177.3 keV). e 4% oﬀset was used to
minimize the spillover of the 99mTc photopeak into the 123I
photopeak. Aer the SPECT acquisition was complete, the
patient remained still on the table for the CT acquisition.
A topogram scout scan (130 kVp, 30mA, anterior view)
was performed �rst, and limits for the CT acquisition were
set (from the neck to the diaphragm). en, a helical CT
scan was performed (130 kVp, 2 × 2.5mm collimation, 0.8 s
rotation time, 1.5 pitch). e dose was controlled by tube-
current modulation (CARE Dose AEC+DOM; Siemens),
with the reference exposure set to 30mAs.
Finally, a static 10-minute anterior image of the neck
and chest was acquired using a low-energy, high-resolution
collimator with a Siemens Symbia T-gamma camera (256 ×
256 matrix; 1.85x zoom (32.2 cm �eld)). e same energy
settings as those in the SPECT acquisition were used. Eleven
of the patients did not complete this �nal image due to limited
camera time or patient-related reasons. A 99mTc intrinsic
�ood was used for both energy windows in both cameras. It
was veri�ed that the image-�eld uniformity was acceptable
for all energy windows used.
2.3. Image Processing. All planar images were analyzed in a
Hermes workstation (Hermes Medical Solutions). For dual-
tracer images, a normalization factor (NF) was de�ned as
the ratio of the thyroid maximum pixel counts in the 123I
and 99mTc-sestamibi images. Gradient subtraction images
were created by multiplying the 99mTc-sestamibi image with
10 successive NFs (with 20% steps from 20% to 200% of
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Starting time
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Image set
Planar AP
LEHR collimator
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LEHR collimator
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LEHR collimator
10-minute image
1
Raw data 123I99mTc-MIBI
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2 34 5
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123I-
reconstruction
99mTc-123I
normalization
and
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99mTc-123I
normalization
and
subtraction 99mTc-123I
1 h 1 h 35 min
normalization and subtraction
F 1: e orders and the timings of the acquisitions and the resulting image sets. Set 1: 99mTc-sestamibi, 123I, and subtraction images
with parallel-hole collimator. Set 2: 99mTc-sestamibi, 123I, and subtraction images with pinhole collimator. Set 3: 99mTc-sestamibi double phase
images with parallel-hole collimator. Set 4: 99mTc-sestamibi SPECT/CT. Set 5: 99mTc-sestamibi, 123I, and subtraction SPECT/CT images.
the original NF), and the 123I image was subtracted from
each normalized 99mTc-sestamibi image, resulting in 10
subtraction images to avoid oversubtraction [9, 10]. e
�nal image sets consisted of 99mTc-sestamibi and 123I images
and gradient subtraction images (image set 1 acquired with
LEHR, image set 2 with pinhole). 99mTc-sestamibi early- and
late-phase images were displayed side-by-side on the Hermes
workstation (image set 3).
SPECT images were reconstructed on the Siemens Syngo
workstation (Siemens) using the FLASH 3D algorithm (8
iterations, 8 subsets, �aussian 9.00 �lter). No scatter cor-
rection was used. e initial NF was de�ned as the ratio of
the corresponding thyroid maximum voxel counts in 99mTc-
sestamibi and 123I SPECT data. 123I SPECT data were multi-
plied byNF to create normalized 123I SPECTdata, whichwere
then subtracted from 99mTc-sestamibi SPECT data to create
the subtraction SPECT dataset, as described by Neumann
and coworkers [4].e NF was adjusted until the subtraction
SPECT images were subjectively satisfactory. CT data were
reconstructed on the Siemens Syngo workstation (Siemens)
for attenuation correction using the B08s kernel, and for
fusion display purposes with a B40s medium kernel. e
CT images were downsampled to match the SPECT image
matrix and converted from Houns�eld units into e�ective
attenuation values at 140 keV (99mTc) and 159 keV (123I).
e �nal image sets consisted of 99mTc-sestamibi SPECT/CT
data (image set 4) and 123I, 99mTc-sestamibi, and subtraction
SPECT/CTdata (image set 5).e accuracy of the SPECT/CT
data coregistration was checked. All image processing was
performed by an experienced medical physicist.
2.4. Image Interpretation. All patient image datasets were
anonymized before review by four experienced nuclear
medicine physicians, who were blinded to all patient-related
information. Five image sets (Figure 1) were reviewed.
Datasets 1, 2, and 3 were read in separate reading sessions.
Image sets 4 and 5 were reviewed in a single session in
this order, with the physician being aware that the datasets
belonged to the same patient.
Each quadrant in relation to the thyroid gland (right
upper, right lower, le� upper, and le� lower) was classi�ed on
a 3-point scale (0 = negative, 1 = uncertain, and 2 = positive).
e image review criteria for positive �nding were as follows:
(a) for image sets 1 and 2: clear abnormal residual activity
on the planar subtraction images, (b) for image set 3: focally
increased uptake that persisted or increased in intensity from
early to late images, (c) for image set 4: focally increased
uptake outside the normal 99mTc-sestamibi biodistribution
that had an anatomic correlation in the CT images, and
(d) for image set 5: clear abnormal residual activity on the
subtraction SPECT images that had an anatomic correlation
in the CT images.
2.5. Surgery and Histologic Analysis. All patients were oper-
ated upon by an endocrine surgeon using an open technique.
e surgeon was aware of all initial scintigraphic results prior
to surgery. All glands were not identi�ed for all patients.
Postoperative iPTH and Ca values were reviewed to con�rm
surgery success.emean interval between scintigraphy and
surgery was 181 days (range, 29–457 days). A histopatholog-
ical analysis was performed for all excised tissue.
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2.6. Data Analysis. To estimate the sensitivity, speci�city, and
accuracy for the localization for each image set, scores of 0-
1 were considered negative and scores of 2 were considered
positive. Findings were classi�ed as true positive, false posi-
tive, true negative, or false negative with histologic analysis as
the reference standard. For each patient, four scores, one for
each quadrant, were assigned. e false-positive image rate
was de�ned as the ratio of false positives to the sum of true
positives plus false positives [11].
2.7. Statistical Methods. e sensitivity, speci�city, and accu-
racy of each image set were calculated for each physician
separately. A McNemar test was performed to compare the
sensitivities, speci�cities, and accuracies between the image
sets.e results from physician 1 were chosen when compar-
ing the image sets, as he had the most experience with the
imaging methods and techniques used. e Mann-Whitney
𝑈𝑈 nonparametric test was used to compare the size of the
visualized and nonvisualized glands. A McNemar test was
also used to analyze the accuracy of the diﬀerent physicians.
e diﬀerences for each method/technique were analyzed
separately. 𝜅𝜅 coeﬃcients were used to quantify the agreement
between the results from the four physicians. Positive kappa
values within the ranges of 0.01–0.20, 0.21–0.4, 0.41–0.60,
0.61–0.80, and 0.81–1.00 were interpreted as “very weak,”
“weak,” “medium,” “good,” and “very good” agreement,
respectively [12]. A 𝑃𝑃 value <0.05 was considered statistically
signi�cant. Statistical analyses were conducted using SAS
9.2 (SAS Institute Inc., Cary, NC, USA) and SPSS statistical
analysis soware (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Histological Findings. Altogether, 30 enlarged glands
were found in 24 patients. Twenty patients had a solitary
parathyroid adenoma, two patients had double adenomas,
and two patients had multiglandular disease. e mean
weight of the abnormal parathyroid glands was 677mg
(weight information was not available for four glands).
e postoperative serum Ca values were normalized for
all patients. e postoperative iPTH values were normalized
for 17 patients. For 7 patients, these values were slightly
elevated (ranged from 80 ng/L to 134 ng/L (mean 90 ng/L),
but decreased from the preoperative values (ranged from
138 ng/L to 400 ng/L (mean 165 ng/L)). Four glands were
visualized in the operation for these patients.
e pathological �ndings together with the image �nd-
ings for physician 1 are listed in Table 1.
3.2. 99𝑚𝑚𝑇𝑇c-Sestamibi versus 123I/99𝑚𝑚𝑇𝑇c-Sestamibi. All image
sets with 123I/99mTc-sestamibi were signi�cantly more sensi-
tive than any image set with 99mTc-sestamibi, regardless of
the acquisition technique (Tables 2 and 3). 99mTc-sestamibi
SPECT/CT (image set 4) had the highest speci�city (100%),
as there were no false-positive readings (Table 2).
99mTc-sestamibi SPECT/CT revealed only 4 abnormal
glands, while 123I/99mTc-sestamibi subtraction SPECT/CT
revealed 23 abnormal glands (Table 1). A representative
patient case is shown in Figure 2.
3.3. Planar AP with LEHR versus Planar AP with Pinhole
versus SPECT/CT. ere was no diﬀerence in the sensitivity,
speci�city, or accuracy between the acquisition techniques
using 99mTc-sestamibi alone. ere was also no diﬀerence in
the sensitivity, speci�city, or accuracy between the acquisi-
tion techniques using 123I/99mTc-sestamibi (Tables 2 and 3).
Although there was no diﬀerence in the sensitivity,
SPECT/CTmay oﬀer invaluable three-dimensional informa-
tion about the location of the enlarged parathyroid adenomas
together with anatomical information (Figure 3).
3.4. False-Positive Findings. Ten patients had 12 diﬀerent
false-positive �ndings (40 false-positive �ndings if all physi-
cians and image sets are summed up). e false-positive
�ndings are presented in Table 4.
Four of these were due to cold thyroid nodules in 123I
images, causing erroneous interpretation in the subtraction
image (Figure 4). Uneven 123I uptake caused thus 55% of all
false-positive �ndings.
One patient had clear uptake in the 99mTc-sestamibi
image below the thyroid as seen in planar images. All
physicians interpreted this as a positive �nding in the planar
images. In the SPECT/CT images, it was revealed that the
uptake was in the cervical vertebra (Figure 5). is bone
uptake caused 20% of all false-positive �ndings.
ree false positive �ndings were due to the “edge eﬀect”
in 123I/99mTc-sestamibi subtraction SPECT/CT images
(residual activity around the thyroid lobes aer subtraction).
is artefact caused 10% of all false-positive �ndings.
Four positive �ndings were caused by an error in image
interpretation, mainly in double phase 99mTc-sestamibi
images. Diﬃculty in setting the line between the positive and
the negative �ndings caused 15% of all false-positive �ndings.
As seen in Table 4, 123I/99mTc-sestamibi dual-tracer
method with various acquisition techniques produced 90%
of all false-positive �ndings. Subtraction SPECT/CT yielded
the lowest percentage of false positives when compared to
the other subtraction methods. e double phase 99mTc-
sestamibi method produced only 10% of all false-positive
�ndings. e false-positive image rate (%) is presented in
Table 5.
3.5. False-Negative Findings. ere was only one abnormal
parathyroid gland (number 10, Table 1) that was visual-
ized in all image sets and by all of the physicians. us
23 patients had 29 diﬀerent false-negative �ndings (267
false-negative �ndings if all physicians and image sets are
summed up). 99mTc-sestamibi/123I subtraction planar images
with parallel-hole collimator produced 13.9% of all false-
negative �ndings, 99mTc-sestamibi/123I subtraction planar
images with pinhole collimator produced 9.7% of all false-
negative �ndings, 99mTc-sestamibi double phase images with
parallel-hole collimator produced 22.8% of all false-negative
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T 1: Number of adenomas and hyperplastic glands and image �ndings for physician 1.
Patient number Gland number Weight (mg) Findings for image set
1 2 3 4 5
1 1 170 FN FN NA FN FN
1 2 570 TP TP NA FN TP
2 3 980 TP TP FN FN TP
3 4 830 TP TP FN TP TP
4 5 1280 TP TP FN FN TP
4 6 840 TP FN FN FN TP
4 7 2140 TP TP FN FN TP
5 8 NA TP TP NA FN TP
6 9 1200 TP TP NA FN TP
7 10 960 TP TP TP TP TP
8 11 1880 TP TP TP FN TP
9 12 1160 FN TP FN FN FN
10 13 299 TP TP FN FN TP
11 14 200 FN FN FN FN FN
12 15 260 TP TP FN FN TP
13 16 570 TP TP TP TP TP
14 17 370 TP TP FN FN TP
15 18 300 TP FN NA FN FN
15 19 400 TP TP NA FN TP
15 20 NA TP TP NA FN TP
16 21 510 TP TP NA FN TP
17 22 340 TP TP FN FN TP
18 23 NA TP TP TP FN TP
19 24 420 FN FN TP FN FN
20 25 300 FN TP NA FN FN
20 26 NA TP TP NA FN TP
21 27 520 TP TP NA FN TP
22 28 400 TP TP FN FN TP
23 29 550 TP TP TP TP TP
24 30 160 FN FN FN FN FN
TP: true positive for abnormal parathyroid gland; FN: false negative for abnormal parathyroid gland; NA: image set not available for patient.
(a) (b)
F 2: 99mTc-sestamibi SPECT (a) and 123I/99mTc-sestamibi subtraction SPECT (b) coronal images for a 34-year-old man with secondary
hyperparathyroidism. ree hyperplastic parathyroid glands not visualized in coronal 99mTc-sestamibi image are clearly visible in the
subtraction SPECT coronal image (b).
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T 2: Sensitivity, speci�city, and accuracy for localization of abnormal parathyroid glands.
Image set Physician Sensitivity (%) Speci�city (%) Accuracy (%)
1
1 80.0 93.9 89.6
2 70.0 95.5 87.5
3 63.3 97.0 86.5
4 63.3 97.0 86.5
2
1 80.0 92.4 88.5
2 80.0 93.9 89.6
3 76.7 95.5 89.6
4 76.7 95.5 89.6
3
1 31.6 93.9 76.5
2 21.1 98.0 76.5
3 10.5 100.0 75.0
4 15.8 100.0 76.5
4
1 13.3 100.0 72.9
2 16.7 100.0 74.0
3 10.0 100.0 71.9
4 10.0 100.0 71.9
5
1 76.7 92.4 87.5
2 76.7 95.5 89.6
3 56.7 98.5 85.4
4 63.3 98.5 87.5
T 3: Statistical signi�cance for di�erences in sensitivity, speci�city, and accuracy for comparisons of image sets for physician 1.
Compared image sets 𝑃𝑃 for sensitivity 𝑃𝑃 for speci�city 𝑃𝑃 for accuracy
1 versus 2 NS NS NS
1 versus 3 0.0117 NS 0.0352
1 versus 4 1.907𝐸𝐸 𝐸 0𝐸 0.0455 0.0015
1 versus 5 NS NS NS
2 versus 3 0.0117 NS NS
2 versus 4 1.907𝐸𝐸 𝐸 0𝐸 0.0253 0.0041
2 versus 5 NS NS NS
3 versus 4 NS NS NS
3 versus 5 0.0117 NS NS
4 versus 5 3.815𝐸𝐸 𝐸 0𝐸 0.0253 0.0066
NS: not signi�cant.
�ndings, 99mTc-sestamibi SPECT/CT produced 39.3% of all
false-negative �ndings, and 99mTc-sestamibi/123I subtraction
SPECT/CT produced 14.2% of all false-negative �ndings (all
physicians and all image sets are summed up).
e smallest gland located in this series was 260mg.
ere were three smaller abnormal parathyroid glands
(160mg, 170mg, and 200mg) that could not be located with
any method or imaging technique by any of the physicians.
e mean gland size of false-negative and true-positive
�ndings for all physicians and image sets are presented in
Table 6 together with the statistical signi�cance.
3.6. Interobserver Variability. e 𝜅𝜅 coeﬃcient for the agree-
ment of the results between the four physicians for the �ve
study readings are shown in Table 7.
e highest agreement for accuracy was found for 99mTc-
sestamibi SPECT/CT, which did not have any false-positive
�ndings for any physician. e highest agreement for sen-
sitivity was found for the planar subtraction images of
123I/99mTc-sestamibi with the pinhole collimator.
4. Discussion
Our results clearly show that a dual-tracer method with
99mTc-sestamibi and 123I is superior to a single-tracermethod
with 99mTc-sestamibi for PS, regardless of the acquisition
technique used. is has been proposed by other authors as
well [4, 9, 13, 14].
To our �nowledge, this is the �rst study comparing planar
imaging with parallel-hole and pinhole collimators using the
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T 4: �e false-positive �ndings for all physicians.
Image set 1 2 3 5
Reason for FP % of FP
Patient number Physician Physician Physician Physician
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
2 RL RL
Uneven iodine uptake 553 RL RL RL RL RL RL RL RL RL RL
8 RU RU
22 RU RU RU RU RU RU RU RU
20 RL RL RL RL RL RL RL RL Bone uptake 20
4 LL
Edge eﬀect 1010 LL
24 RU RU
24 LL
Other 1524 RL RL RL
13 LU
19 LL
% of FP 27.5 37.5 10 25
FP: false positive, RU: right upper, RL: right lower, LU: le upper, and LL: le lower.
(a) (b) (c)
F 3:A 99mTc-sestamibi uptake in a parathyroid adenoma located behind the trachea. 123I/99mTc-sestamibi subtraction SPECT/CT images
(transversal (a), sagittal (b), and coronal (c)).
(a) (b) (c)
F 4: A cold nodule in the upper quadrant of a right thyroid lobe in the 123I image (b) causing a false-positive �nding in the subtraction
image (c).
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(a) (b) (c)
(d) (e) (f)
F 5: A 99mTc-sestamibi focal uptake inferior to the thyroid seen in the anterior image acquiredwith a pinhole collimator. 99mTc-sestamibi
(a), 123I (b), and subtraction image (c). All physicians interpreted this uptake as an abnormal parathyroid gland. e same patient seen in
123I/99mTc-sestamibi subtraction SPECT/CT images (transversal (d), sagittal (e), and coronal (f)). Focal uptake was due to bone uptake in the
cervical vertebra.
T 5: e false-positive image rate (%) for each image set and each physician.
Physician False-positive rate (%) for image set
1 2 3 4 5
1 14.3 17.2 33.3 0.0 17.9
2 12.5 14.3 20.0 0.0 11.5
3 9.5 11.5 0.0 0.0 5.6
4 2.1 3.1 0.0 0.0 1.0
Average 9.6 11.5 13.3 0.0 9.0
T 6: e mean gland size of false-negative and true-positive �ndings for all physicians and all image sets.
Image set
1 2 3 4 5
Smallest gland visualized 260 260 420 550 260
Mean weight of FN (mg) 300 420 485 420 300
Mean weight of TP (mg) 560 570 960 830 560
𝑃𝑃 (FN versus TP) 0.002 <0.001 0.046 0.026 <0.001
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T 7: e comparison of reader agreement (accuracy and sensitivity) between physicians.
𝜅𝜅 coeﬃcient for Physicians Image set
1 2 3 4 5
Accuracy
1 versus 4 0.56 0.84 0.67 0.97 0.62
1 versus 3 0.56 0.84 0.72 0.97 0.56
1 versus 2 0.69 0.84 0.59 0.92 0.69
4 versus 3 1.00 1.00 0.96 1.00 0.91
4 versus 2 0.86 0.78 0.84 0.89 0.59
3 versus 2 0.86 0.78 0.88 0.89 0.53
Sensitivity
1 versus 4 0.44 0.90 0.30 0.84 0.69
1 versus 3 0.44 0.90 0.41 0.84 0.57
1 versus 2 0.56 1.00 0.20 0.61 0.81
4 versus 3 1.00 1.00 0.77 1.00 0.86
4 versus 2 0.85 0.90 0.48 0.43 0.69
3 versus 2 0.85 0.90 0.61 0.43 0.57
123I/99mTc-sestamibi subtraction method with patients. We
could not demonstrate the improved sensitivity from the use
of the pinhole collimator that has been shown by several
authors when using 99mTc-sestamibi [15–20].
SPECT alone has been shown to improve sensitivity
compared with planar imaging with parallel-hole collimators
[6, 21–24]. SPECT/CT has been shown to oﬀer precise
anatomical localization and an improvement in diagnostic
speci�city and accuracy over conventional SPECT, especially
for patients with previous neck surgery or multiglandular
disease [5, 25–32]. e use of SPECT/CT also shortens
surgical times (when compared with SPECT alone) and
eventually lowers costs [33, 34]. Opposite opinions have also
been presented, and the use of SPECT/CT has been found to
be important only for locating ectopic parathyroid adenomas
[35, 36].
We could not demonstrate an increased sensitivity for
123I/99mTc-sestamibi subtraction SPECT/CT when com-
pared with planar 99mTc-sestamibi/123I subtraction image
sets. However, the use of 123I/99mTc-sestamibi SPECT/CT
decreased the false-positive rate for three observers when
compared with planar 123I/99mTc-sestamibi image sets.
e low sensitivity of double phase planar 99mTc-
sestamibi or 99mTc-sestamibi SPECT/CT cannot be explained
by the rapid washout of 99mTc-sestamibi, as 19 enlarged
parathyroid glands were visible in 123I/99mTc-sestamibi
SPECT/CT images that could not be visualized with 99mTc-
sestamibi SPECT/CT. A low sensitivity for a single tracer or
the double phase protocols has also been reported by other
authors [3, 37].
e low sensitivity of the 99mTc-sestamibi SPECT/CT in
this study could not be linked to the timing of the acquisi-
tion. SPECT acquisition was started approximately one hour
aer 99mTc-sestamibi injection. Lavely and coworkers were
able to demonstrate much better sensitivity for early-phase
SPECT/CT (62%) and also for early planar/delayed planar
imaging (56,5%) [5]. e timing of their early planar and
SPECT/CT acquisitions was almost identical to ours.
Our results for the 123I/99mTc-sestamibi subtraction
SPECT/CT are comparable to the results of Neumann and
coworkers [26], who demonstrated a sensitivity of 70% and
a speci�city of 96% in a group of 61 patients with primary
hyperparathyroidism.e increase of speci�city (when com-
pared with SPECT alone) was explained by reducing the
number of false positives.
ere were three abnormal parathyroid glands that were
visible in 123I/99mTc-sestamibi subtraction planar images
(with a parallel-hole or a pinhole collimator) but not visible
in 123I/99mTc-sestamibi subtraction SPECT/CT. is could
be due to rapid washout [38] as SPECT/CT was performed
one hour later than the planar images were acquired. us,
the timing of the various acquisitions should be considered
carefully, and SPECT/CT should be performed in the early
phase so as not to miss abnormal parathyroid gland(s) with
rapid washout [10].
e average false-positive rate was comparable to previ-
ous reports [6, 11]. In this retrospective study, the �ve image
sets were not reviewed together, which is normally done in
our clinical scenario. With careful observation of the 123I
images of the thyroid, it should be possible to decrease the
false-positive rate in subtraction images.
It seems that a major factor in�uencing detection of
abnormal parathyroid glands is their size. e diﬀerence of
mean gland size of false-negative and true-positive �ndings
was statistically signi�cant for all protocols used in this study.
ere was lower number of ectopic glands in this patient
group than could be expected [39]. ere might have been
small ectopic glands which were not recognized in scintig-
raphy or in surgery. is might explain the slightly elevated
iPTH values for 7 patients.
Several imaging protocols for PS with 99mTc-sestamibi
are in use, with a wide range of sensitivities (34–100%)
reported [8]. No large study exists that compares the accu-
racy of each [6]. We have shown the superiority of the
123I/99mTc-sestamibi subtraction method of PS. e high
popularity of the single-tracer method with 99mTc-sestamibi
alone can only be explained by its technical simplicity. It
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is true that the 123I/99mTc-sestamibi subtraction method,
especially SPECT/CT, is technically demanding. ere are
several possible sources of artifacts, such as scaling and
the subtraction process. In our opinion, the data processing
should be performed by an experienced medical physicist.
Even optimal processing of identical 99mTc and 123I
targets does not give �awless subtraction image, some activity
is always le around the edges. In this series, it was in few
cases interpreted as a positive �nding. To our knowledge, this
artefact has not been described earlier concerning parathy-
roid scintigraphy [40].
e overall interobserver agreement in this study was
good. e average 𝜅𝜅 coeﬃcient was 0.79 for accuracy and
0.70 for sensitivity. ese results are comparable to previous
results [12, 15].
One of the main limitations of this study is the number
of patients in the image set 3 (99mTc-sestamibi double phase
images). Another limitation of our study relates to the fact
that the delay phase was acquired with another gamma cam-
era. However, quality assurance measurements are routinely
performed for both cameras. ere are no diﬀerences in
important parameters regarding image quality.
e clinical PS protocol presented in this study, which
included various acquisitions, is quite time consuming.
e discomfort for the patient should be decreased by
rejecting unnecessary acquisitions. is study indicates
that the 123I/99mTc-sestamibi subtraction method combined
with any imaging technique is adequate to locate abnor-
mal parathyroid glands. However, 123I/99mTc-sestamibi sub-
traction SPECT/CT is recommended because it provides
accurate three-dimensional information about the location
of enlarged parathyroid adenomas together with anatom-
ical information (Figure 3) and may in�uence the surgi-
cal approach [14]. With SPECT/CT, it is also possible to
avoid some false-positive �ndings resulting from the 99mTc-
sestamibi uptake in bone structures. e additional use of
anterior pinhole images may be useful for recognizing cold
thyroid nodules and thus further reducing the false-positive
rate. Determining the optimal technical aspects (acquisition
and processing parameters, various physical corrections) still
requires further study.
5. Conclusion
e results of this study show that the 123I/99mTc-sestamibi
subtraction method combined with any imaging tech-
nique is superior for enlarged parathyroid gland local-
ization when compared with 99mTc-sestamibi alone with
any acquisition technique. 123I/99mTc-sestamibi subtraction
SPECT/CT is recommended because it provides accu-
rate three-dimensional information about the location of
enlarged parathyroid adenomas. e use of anterior pinhole
images may be useful for recognizing cold thyroid nodules
and thus reducing the false-positive rate.e overall interob-
server agreement for accuracy and for sensitivity in this study
was good. us the parathyroid scintigraphy is independent
of the reporter.
ere are two limitations that need to be acknowledged
regarding this study. e �rst limitation is the number of
patients in the 99mTc-sestamibi double phase group. Another
limitation relates to the fact that the delay phase was acquired
with another gamma camera.
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